The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …

To address the continued rise of multi-drug-resistant microorganisms, the development of
novel drugs with new modes of action is urgently required. While humans biosynthesize the …

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver
cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been …

We conducted an adaptive design single‐center pilot trial between October 2017 and
November 2018 to determine the safety and efficacy of ultra‐short‐term perioperative …

Introduction: The development of direct-acting antiviral (DAA) agents for the treatment of
hepatitis C virus (HCV) infection has completely transformed the management of this …

Trials describing 4‐to 12‐week courses of direct‐acting antiviral drugs (DAAs) to treat
hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant …

Introduction Pharmacotherapy against hepatitis C virus (HCV) infection has tremendously
improved since the advent of interferon (IFN)-free direct-acting antivirals (DAAs) …

Liver transplantation (LT) using allografts from hepatitis C virus (HCV)‐viremic/nucleic acid
testing–positive donors'(DNAT+) organs into HCV‐aviremic recipients (rHCV−) has been …

Conclusions: Baseline NS5A-RAS can compromise the efficacy of double-DAA
pangenotypic regimens for HCV genotype 3, and enhanced viral fitness can accelerate …

Tuberculosis (TB) and hepatitis C virus (HCV) infections are both major public health
problems. Despite high rates of coinfection, there is scarce literature addressing the …